Statistics from Altmetric.com
Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes—an interim analysis. N Engl J Med 2007;357:28–38.
Clinical impact ratings GP/FP/Primary care ★★★★★★⋆ Cardiology ★★★★★★⋆ Endocrine ★★★★★★⋆ Internal medicine ★★★★★⋆⋆
randomised controlled trial (RCT) (Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of glycaemia in Diabetes [RECORD] trial).
unclear allocation concealment.*
blinded (outcome assessors).*
mean 3.75 …
Source of funding: GlaxoSmithKline.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.